Imperial College London
Portrait Picture

Charlie Whittaker

Faculty of Medicine, School of Public Health

Research Fellow
 
 
 
//

Contact

 

charles.whittaker16

 
 
//

Location

 

Sir Michael Uren HubWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Whittaker:2022:10.1101/2022.05.18.22275185,
author = {Whittaker, C and Chesnais, CB and Pion, SDS and Kamgno, J and Walker, M and Basáñez, M-G and Boussinesq, M},
doi = {10.1101/2022.05.18.22275185},
title = {Factors associated with variation in single-dose albendazole pharmacokinetics: A systematic review and modelling analysis},
url = {http://dx.doi.org/10.1101/2022.05.18.22275185},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - <jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Albendazole is an orally administered anti-parasitic medication with widespread usage in a variety of both programmatic and clinical contexts. Previous work has shown the drug to be characterised by significant inter-individual pharmacokinetic variation. This variation is thought to have important consequences for treatment success, but current understanding of the factors associated with this variation remains incomplete.</jats:p></jats:sec><jats:sec><jats:title>Methodology/Principal Findings</jats:title><jats:p>We carried out a systematic review to identify references containing temporally disaggregated data on the blood concentration of albendazole and/or (its pharmacologically-active metabolite) albendazole sulfoxide following a single oral dose. These data were then integrated into a mathematical modelling framework to infer key pharmacokinetic parameters and relate them to characteristics of the populations being treated. These characteristics included age, weight, sex, dosage, infection status, and whether patients had received a fatty meal prior to treatment or other drugs alongside albendazole. Our results highlight a number of factors systematically associated with albendazole pharmacokinetic variation including age, existing parasitic infection and receipt of a fatty meal. These factors impact different aspects of the drug’s pharmacokinetic profile. Whilst age is significantly associated with albendazole sulfoxide half-life, receipt of a fatty meal prior to treatment was associated with increased albendazole bioavailability (and by extension, peak blood concentration and total drug exposure following the dose). Parasitic infection (particularly echinococcosis and neurocysticercosis) was associated with altered pharmacokinetic parameters, with infected populations displaying distinct characteris
AU  - Whittaker,C
AU  - Chesnais,CB
AU  - Pion,SDS
AU  - Kamgno,J
AU  - Walker,M
AU  - Basáñez,M-G
AU  - Boussinesq,M
DO  - 10.1101/2022.05.18.22275185
PY  - 2022///
TI  - Factors associated with variation in single-dose albendazole pharmacokinetics: A systematic review and modelling analysis
UR  - http://dx.doi.org/10.1101/2022.05.18.22275185
ER  -
Download